DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, a…
Medical - Devices
US, San Diego [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 1.90 | 2.90 | 2.84 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 37.32 | 9.17 | 6.68 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 6.92 | 5.76 | 5.39 | |
| Cash | 4.68 | 7.42 | 7.09 | |
| Capex | -6.69 | -0.15 | -0.14 | |
| Free Cash Flow | 84.86 | 0.39 | 0.21 | |
| Revenue | -12.36 | 2.36 | 2.69 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -3.88 | 0.61 | 0.63 | |
| Operating Margin | -47.64 | 0.11 | 0.21 | |
| ROA | -44.80 | 0.02 | 0.04 | |
| ROE | -47.41 | 0.07 | 0.12 | |
| ROIC | -52.31 | 0.02 | 0.05 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of DXCM is permitted for members.
5
Growth
The "Growth Entry" for the Focus of DXCM is permitted for members.
6
Leverage & Liquidity